mobocertinib
Selected indexed studies
- Mobocertinib. (, 2012) [PMID:37988546]
- Mobocertinib: First Approval. (Drugs, 2021) [PMID:34716908]
- Mobocertinib: Mechanism of action, clinical, and translational science. (Clin Transl Sci, 2024) [PMID:38511563]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Mobocertinib. (2012) pubmed
- Mobocertinib: First Approval. (2021) pubmed
- Mobocertinib: Mechanism of action, clinical, and translational science. (2024) pubmed
- Mobocertinib in non-small cell lung cancer. (2022) pubmed
- Mobocertinib Succinate. (2022) pubmed
- Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies. (2024) pubmed
- First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. (2025) pubmed
- Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations. (2022) pubmed
- Clinical Utility of Mobocertinib in the Treatment of NSCLC - Patient Selection and Reported Outcomes. (2023) pubmed
- Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations. (2021) pubmed